North America Research Institute | NARI San Dimas, CA - Other PI's

Research site

Location

1335 W. Cypress Street Suite 204, San Dimas, California, United States of America

Site insights

Top conditions

Top treatments

Clazakizumab

Apricoxib

Lanthanum Carbonate

Gemcitabine

Calcifediol

Capecitabine

Vicadrostat

SNF472

MK-2060

Evinacumab

Parent organization

This site is a part of North America Research Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Molly Way

Verified by this site

Active trials

7 of 20 total trials

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receivi...

Enrolling

End Stage Renal Disease on Dialysis

Chronic Kidney Disease Requiring Chronic Dialysis

Drug: AP306 75 mg TID

Drug: AP306 150 mg BID

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

PODOMOUNT-pFSGSThis study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of...

Enrolling

Focal Segmental Glomerulosclerosis

Drug: BI 764198

Drug: Placebo

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication...

Active, not recruiting

Chronic Kidney Disease

Drug: Vicadrostat

Drug: Empagliflozin

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study.Part 1...

Enrolling

End Stage Kidney Disease

Drug: Placebo

Drug: CSL300

Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants

The purpose of this study is to evaluate the safety and efficacy of the Moda-flx Hemodialysis System™ when used Under Professional Care Settings by t...

Enrolling

End Stage Kidney Disease

Device: Moda-flx Hemodialysis System™

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease (ANCHOR-POC)

This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have dia...

Enrolling

Diabetic Kidney Disease (DKD)

Drug: Evinacumab

Drug: ALN-ANG3 placebo

VE303 for Prevention of Recurrent Clostridioides Difficile Infection (RESTORATiVE303)

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week...

Enrolling

CDI

C.Difficile Diarrhea

Biological: Placebo

Biological: VE303